Benefits
Strength and high-intensity exercise performance
Creatine monohydrate consistently improves strength, power output, and high-intensity exercise performance across hundreds of clinical trials. Effects are seen in trained and untrained populations, with the largest gains in resistance training and short-duration sprint work.
Lean body mass and muscle hypertrophy
Combined with resistance training, creatine monohydrate increases lean body mass and muscle cross-sectional area more than training alone. Effects appear over 4-12 weeks of consistent use at 3-5 g/day, with continued gains over months.
Improved muscle recovery between sessions
Creatine reduces markers of muscle damage and supports faster recovery between training sessions. Useful for high-frequency training, sports with multiple competitions, or anyone training muscle groups more than twice weekly.
Cognitive benefits, especially under stress
Creatine supports cognitive performance during sleep deprivation, mental fatigue, and demanding tasks. In the cited meta-analyses the effect is modest and concentrated in older adults: memory improved in adults aged 66 to 76 (SMD 0.88) but was minimal in younger adults (SMD 0.03), with an overall memory effect of SMD 0.31 across 16 trials. The clearest result in healthy young adults comes from a single high-dose trial during 21 hours of sleep deprivation. On the cited evidence this is a modest effect in older adults or under metabolic stress, not a general nootropic for healthy young people.
Bone health in postmenopausal women (emerging research)
Combined with resistance training, creatine monohydrate at 5 g/day has been studied for bone health, but this outcome is not covered by the studies cited on this page. The older-adult meta-analysis referenced here (Chilibeck 2017) measured lean tissue mass and muscular strength, not bone mineral density. Any bone-related effect should be treated as emerging and is thought to be indirect, through muscle-bone signaling during resistance training.
Brain energy metabolism in aging (preclinical)
Animal studies and emerging human evidence suggest creatine supports brain energy metabolism and may have neuroprotective effects in aging. This work is early stage and largely preclinical, and none of the studies cited on this page tested a neurological condition — the cited ISSN position stand lists neuroprotection as a potential application, not an established one. Creatine is not a treatment for any disease.
Hydration and cell volumization
Creatine draws water into muscle cells (intramuscular hydration), supporting cellular volume and signaling pathways that promote muscle growth. This accounts for the initial 1-3 kg weight gain at the start of supplementation, which is intracellular water in muscle rather than subcutaneous fluid; whether that is welcome depends on the individual and the sport.
Established safety record
Decades of research and use in millions of athletes confirm an excellent safety profile in healthy adults at standard doses. No documented kidney or liver toxicity in healthy users. Adequate hydration is sensible during use.
Mechanism of action
Phosphocreatine system — rapid ATP regeneration
Creatine kinase catalyzes the transfer of a phosphate group from phosphocreatine to ADP, regenerating ATP in milliseconds. This is the dominant energy system for the first 5-10 seconds of maximal effort, before glycolysis takes over. Supplementation increases muscle phosphocreatine concentration by roughly 20-40%, expanding the size of this fast-turnover energy reservoir. More phosphocreatine means more reps at high intensity before failure — the primary mechanism behind the strength and hypertrophy effects.
Cell volumization
Creatine is osmotically active inside muscle cells. Increased intracellular creatine draws water into the cell, which is associated with anabolic signaling and is thought to contribute to muscle protein synthesis independently of the training-quality effect. This is the source of the early 1-3 kg weight gain seen with loading.
Direct anabolic signaling
Beyond cell volumization, creatine appears to influence satellite cell activity, IGF-1 expression, and myogenic regulatory factors. These effects are smaller than the indirect 'better training' pathway but contribute to the lean mass results in well-controlled trials.
Brain energy metabolism
The phosphocreatine system also operates in brain tissue, particularly during high-demand cognitive tasks and metabolic stress. The blood-brain barrier limits creatine uptake — brain creatine increases are smaller (3-10%) and slower than muscle increases, and require longer or higher-dose protocols to be detectable by MR spectroscopy. This is why cognitive effects are clearest under metabolic stress (sleep deprivation, hypoxia, mild TBI, aging) rather than in healthy young adults at rest.
Why monohydrate, not the alternatives
Creatine HCl, ethyl ester, nitrate, buffered (Kre-Alkalyn), and liquid forms have been marketed as 'better absorbed' or 'more stable' than monohydrate. The ISSN Position Stand and follow-up reviews conclude that no alternative form is superior to monohydrate, and some are inferior. Monohydrate has the cheapest cost per gram, the best stability, and the entire ~500-study evidence base behind it.
Clinical trials
Comprehensive evidence-based review by the International Society of Sports Nutrition.
Evidence-based ISSN expert position stand
Comprehensive evidence-based review by the International Society of Sports Nutrition. Concludes creatine monohydrate is the most effective ergogenic supplement available for high-intensity exercise capacity and lean body mass, is safe at doses up to 30 g/day for short periods and 3-5 g/day long-term, and has potential applications in concussion neuroprotection, sarcopenia, and clinical conditions. Considered the standard reference for clinical and sports nutrition recommendations.
Meta-analysis of 100 randomized, placebo-controlled, blinded human studies (Branch, 2003).
100 placebo-controlled human trials
Creatine produced small but statistically significant gains in lean body mass (effect size 0.17) and in short-duration high-intensity performance (effect size 0.24 for efforts under 30 seconds). Benefits were largest for repetitive, laboratory-based, upper-body resistance tasks and were independent of sex or training status; no benefit was seen for running or swimming.
Systematic review and meta-analysis of 60 randomized controlled trials (Lanhers et al., 2015).
646 supplemented vs 651 control
Across 60 randomized trials, creatine significantly improved lower-limb strength for efforts lasting under 3 minutes, with a global lower-limb effect size of 0.235 (95% CI 0.125-0.346) and clear gains in the squat (ES 0.34) and leg press (ES 0.30). Effects were independent of dose, training protocol, age, and sex.
Companion systematic review and meta-analysis of 53 randomized controlled trials (Lanhers et al., 2017).
563 supplemented vs 575 control
Across 53 randomized trials, creatine significantly improved upper-limb strength for efforts under 3 minutes, with a global upper-limb effect size of 0.317 (95% CI 0.185-0.449), including bench press gains. As in the lower-limb analysis, benefits held regardless of dosing, training status, age, or sex.
Pooled analysis of creatine ingestion strategies in older adults on resistance training.
Older adults on resistance training
Pooled analysis of creatine ingestion strategies in older adults on resistance training. A loading phase plus ≥5 g/day produced the clearest gains in lean mass and lower-body strength. Creatine taken only on training days was sufficient — no advantage to daily dosing. Practical takeaway: protocol matters in older adults more than in young athletes. This pooled analysis of 22 randomized trials in 721 older adults measured lean tissue mass and upper- and lower-body strength; it did not assess bone mineral density.
Sixteen clinical trials, 492 participants aged 20.8-76.4 years.
492 participants across 16 trials (aged 20.8-76.4)
Sixteen clinical trials, 492 participants aged 20.8-76.4 years. Significant effects on memory (SMD 0.31, 95% CI 0.18-0.44), attention time (SMD -0.31), and processing speed (SMD -0.51). No significant effect on overall cognitive function or executive function. Subgroup analyses found benefits more pronounced in disease populations, ages 18-60, and females.
Subgroup analysis showed significant memory improvement in older adults aged 66-76 (SMD 0.88, 95% CI 0.22-1.55) but minimal effect in younger adults (SMD 0.03).
Older adults
Subgroup analysis showed significant memory improvement in older adults aged 66-76 (SMD 0.88, 95% CI 0.22-1.55) but minimal effect in younger adults (SMD 0.03). Dose, duration, sex, and geographical origin did not influence findings — consistent with the view that the benefit is concentrated in populations with reduced baseline brain creatine.
Fifteen healthy adults received a single 0.35 g/kg dose of creatine before 21 hours of sleep deprivation.
15 healthy adults
Fifteen healthy adults received a single 0.35 g/kg dose of creatine before 21 hours of sleep deprivation. 31P-MRS showed significant increases in brain phosphocreatine; subjective fatigue was reduced; cognitive performance was partially preserved. Rare example of a high-dose acute creatine effect in healthy young adults under metabolic stress.
Evidence-based review by an international expert panel addressing 12 common questions (Antonio et al., 2021).
Evidence review (500+ studies)
An expert panel concluded that creatine monohydrate at 3-5 g/day is well tolerated and, in healthy people, does not cause kidney damage, hair loss, dehydration, or muscle cramping, and is not an anabolic steroid. A loading phase is not required, and monohydrate remains the most-studied and recommended form.